Eli Lilly And Stock Performance
| LLY Stock | USD 750.77 0.87 0.12% |
On a scale of 0 to 100, Eli Lilly holds a performance score of 14. The firm shows a Beta (market volatility) of 0.73, which means possible diversification benefits within a given portfolio. As returns on the market increase, Eli Lilly's returns are expected to increase less than the market. However, during the bear market, the loss of holding Eli Lilly is expected to be smaller as well. Please check Eli Lilly's treynor ratio, as well as the relationship between the expected short fall and day median price , to make a quick decision on whether Eli Lilly's price patterns will revert.
Risk-Adjusted Performance
14 of 100
Weak | Strong |
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Eli Lilly and are ranked lower than 14 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak essential indicators, Eli Lilly showed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (0.12) | Five Day Return (1.19) | Year To Date Return 26.78 | Ten Year Return 1.2 K | All Time Return 18.4 K |
Forward Dividend Yield 0.0069 | Payout Ratio 0.7421 | Last Split Factor 2:1 | Forward Dividend Rate 5.2 | Dividend Date 2024-03-08 |
| Eli Lilly dividend paid on 15th of February 2024 | 02/15/2024 |
| Eli Lilly dividend paid on 8th of March 2024 | 03/08/2024 |
1 | Elon Musks X is back to giving out free blue checks. Its no surprise they were a tough sell | 04/04/2024 |
2 | 2 Growth Stocks to Buy Hand Over Fist in April | 04/08/2024 |
3 | Radiopharmaceutical emerges as the hottest space in biotech heres what it means for Clarity Pharma | 04/09/2024 |
4 | Riassunto Gli innovativi biomarcatori per il punteggio Z relativo al grasso AMRA Medical mostrano che il trattamento con tirzepatide associato a un potenziale e... | 04/10/2024 |
5 | Roche granted FDA Breakthrough Device Designation for blood test to support earlier Alzheimers disease diagnosis | 04/11/2024 |
6 | BMO Capital starts Novo Nordisk at Outperform | 04/12/2024 |
| Begin Period Cash Flow | 2.1 B |
Eli |
Eli Lilly Relative Risk vs. Return Landscape
If you would invest 62,781 in Eli Lilly and on January 17, 2024 and sell it today you would earn a total of 12,296 from holding Eli Lilly and or generate 19.59% return on investment over 90 days. Eli Lilly and is generating 0.3022% of daily returns assuming volatility of 1.647% on return distribution over 90 days investment horizon. In other words, 14% of stocks are less volatile than Eli, and above 95% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
Eli Lilly Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Eli Lilly's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Eli Lilly and, and traders can use it to determine the average amount a Eli Lilly's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1835
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | LLY | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 1.65 actual daily | 14 86% of assets are more volatile |
Expected Return
| 0.3 actual daily | 5 95% of assets have higher returns |
Risk-Adjusted Return
| 0.18 actual daily | 14 86% of assets perform better |
Based on monthly moving average Eli Lilly is performing at about 14% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Eli Lilly by adding it to a well-diversified portfolio.
Eli Lilly Fundamentals Growth
Eli Stock prices reflect investors' perceptions of the future prospects and financial health of Eli Lilly, and Eli Lilly fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Eli Stock performance.
| Return On Equity | 0.48 | ||||
| Return On Asset | 0.12 | ||||
| Profit Margin | 0.15 % | ||||
| Operating Margin | 0.34 % | ||||
| Current Valuation | 699.33 B | ||||
| Shares Outstanding | 950.77 M | ||||
| Price To Earning | 54.92 X | ||||
| Price To Book | 66.34 X | ||||
| Price To Sales | 20.94 X | ||||
| Revenue | 34.12 B | ||||
| Gross Profit | 21.91 B | ||||
| EBITDA | 12.46 B | ||||
| Net Income | 5.24 B | ||||
| Cash And Equivalents | 2.07 B | ||||
| Cash Per Share | 2.97 X | ||||
| Total Debt | 25.23 B | ||||
| Debt To Equity | 1.58 % | ||||
| Current Ratio | 1.13 X | ||||
| Book Value Per Share | 11.98 X | ||||
| Cash Flow From Operations | 4.24 B | ||||
| Earnings Per Share | 5.78 X | ||||
| Market Capitalization | 713.81 B | ||||
| Total Asset | 64.01 B | ||||
| Retained Earnings | 10.31 B | ||||
| Working Capital | (1.57 B) | ||||
| Current Asset | 12.57 B | ||||
| Current Liabilities | 8.23 B | ||||
About Eli Lilly Performance
To evaluate Eli Lilly Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Eli Lilly generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Eli Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Eli Lilly market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Eli's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 320.42 | 180.07 | |
| Return On Tangible Assets | 0.10 | 0.14 | |
| Return On Capital Employed | 0.28 | 0.25 | |
| Return On Assets | 0.08 | 0.12 | |
| Return On Equity | 0.49 | 0.26 |
Things to note about Eli Lilly performance evaluation
Checking the ongoing alerts about Eli Lilly for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Eli Lilly help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Over 84.0% of the company shares are owned by institutional investors | |
| On 8th of March 2024 Eli Lilly paid $ 1.3 per share dividend to its current shareholders | |
| Latest headline from investing.com: BMO Capital starts Novo Nordisk at Outperform |
- Analyzing Eli Lilly's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Eli Lilly's stock is overvalued or undervalued compared to its peers.
- Examining Eli Lilly's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Eli Lilly's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Eli Lilly's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Eli Lilly's stock. These opinions can provide insight into Eli Lilly's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Eli Lilly and. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Complementary Tools for Eli Stock analysis
When running Eli Lilly's price analysis, check to measure Eli Lilly's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eli Lilly is operating at the current time. Most of Eli Lilly's value examination focuses on studying past and present price action to predict the probability of Eli Lilly's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eli Lilly's price. Additionally, you may evaluate how the addition of Eli Lilly to your portfolios can decrease your overall portfolio volatility.
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Stocks Directory Find actively traded stocks across global markets |
Is Eli Lilly's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eli Lilly. If investors know Eli will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eli Lilly listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.13 | Dividend Share 4.52 | Earnings Share 5.78 | Revenue Per Share 37.908 | Quarterly Revenue Growth 0.281 |
The market value of Eli Lilly is measured differently than its book value, which is the value of Eli that is recorded on the company's balance sheet. Investors also form their own opinion of Eli Lilly's value that differs from its market value or its book value, called intrinsic value, which is Eli Lilly's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eli Lilly's market value can be influenced by many factors that don't directly affect Eli Lilly's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eli Lilly's value and its price as these two are different measures arrived at by different means. Investors typically determine if Eli Lilly is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eli Lilly's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.